The raised FY guidance and accelerating profitability (GAAP operating income guidance up $250M at midpoint) signal strong momentum. Watch for upcoming regulatory catalysts: BRUKINSA first-line MCL submissions in 2H 2026 and TEVIMBRA FDA action for HER2+ GEA in 2H 2026.
Drugs in focus
ONC drug pipeline →Ziihera
● Neutral Named in this 8-K- Impact
- Phase
- Approved
- Time to market
- Already approved and marketed. First FDA approval was November 2024 (BTC), second was August 2026 (GEA).
- Next catalyst
- None dated
What to watchZiihera is already approved in two indications (BTC and GEA) and generating royalty revenue through partners Jazz and BeOne. The next major catalyst would be a potential regulatory filing for HER2+ colorectal cancer following the August 2026 Breakthrough Therapy Designation, but no PDUFA date has been set. Watch for quarterly royalty revenue growth and any label expansion filings as the key value drivers.
How the stock moved after the report
⚠ Clustered BULLISH VIEWSTOCK ABOVE ENTRY AT T+60- T+0 · Aug 5 $327.53entry
- T+1 · 3mo ago +0.69%α +0.85% · $329.80
- T+5 · 3mo ago +9.62%α +9.27% · $359.05
- T+20 · 3mo ago +10.46%α +11.06% · $361.78
- T+60 · 19d ago +12.55%α +12.36% · $368.64
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
BeOne Medicines reported Q2 2026 revenue of $1.71B (+30% YoY) and GAAP diluted EPS of $2.05/ADS, with raised FY2026 revenue guidance to $6.6B-$6.8B and GAAP operating income guidance to $1.0B-$1.1B. The quarter was driven by BRUKINSA global sales of $1.2B (+31% YoY) and FDA accelerated approval for BEQALZI (sonrotoclax) in RR MCL. The raised guidance and strong operational leverage signal accelerating profitability, making this a clear positive catalyst for the stock.
Key Financial Metrics
Key Facts
- Total Q2 2026 revenue of $1.71B, up 30% YoY from $1.32B
- BRUKINSA global sales of $1.2B, up 31% YoY; U.S. sales $893M (+31%)
- GAAP diluted EPS per ADS of $2.05 vs $0.84 in prior-year period
- Adjusted diluted EPS per ADS of $3.84 vs $2.25 in prior-year period
- GAAP net income of $237M, up 151% YoY from $94M
- Free cash flow of $435M, up 98% YoY from $220M
- Raised FY2026 total revenue guidance to $6.6B-$6.8B from prior $6.3B-$6.5B
- Raised GAAP operating income guidance to $1.0B-$1.1B from $750M-$850M
- BEQALZI (sonrotoclax) received FDA accelerated approval for RR MCL
- Gross margin improved to 90% from 87% in prior-year period
- SGA expenses as % of product sales improved to 35% from 41%
Financial Impact
Revenue beat of ~$85M vs $1.62B consensus; GAAP EPS of $2.05/ADS vs consensus $1.63/ADS; FY guidance raised by $300M at midpoint
Risk Factors
- R&D and SG&A expenses continue to grow (17% and 10% YoY respectively), pressuring margins if revenue growth slows
- Income tax expense surged to $75M from $5M in prior year, potentially reducing net income growth rate
- Diluted ADS count expected at ~118M, up from ~116M in Q2 2026, modest dilution
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001628280-26-052877 |
| Document: bgne-20260805.htm | 0001628280-26-052877 |
| Document: 0001628280-26-052877-index-headers.html | 0001628280-26-052877 |
| Document: 0001628280-26-052877-index.html | 0001628280-26-052877 |
| Document: 0001628280-26-052877.txt | 0001628280-26-052877 |
| 8-K Data (Synthetic) | 0001628280-26-052877 |
Track record
27 reports on ONC
2 of 6 bullish or bearish reports moved the stock their way by T+5. Best: +7.41% at T+5 after the Nov 5, 2026 report. 3 of 6 went positive at some point.
Filters
- Nov 13, 20263d ago SC 13G/A Neutral 2/10 Entry $416.54 Now $416.54 +0.00% settles Nov 23
- Nov 10, 20266d ago Insider Cluster Neutral 3/10 Entry $419.98 Now $416.54 −0.82% settles Nov 18
- Nov 6, 202610d ago 144 Neutral 2/10 Entry $417.33 to $411.29 Now $416.54 −0.19% ▼ −1.45% +0.25% vs SPY
- Nov 5, 202611d ago 144 Neutral 2/10 Entry $406.96 to $416.54 Now $416.54 +2.35% ▲ +2.35% −0.24% vs SPY
- Nov 5, 202611d ago 8-K Bullish 6/10 Entry $387.25 to $415.96 Now $416.54 +7.56% ▲ +7.41% +4.12% vs SPY
- Nov 4, 202612d ago Institutional Cluster Neutral 3/10 Entry $377.78 to $419.98 Now $416.54 +10.26% ▲ +11.17% +12.08% vs SPY
- Oct 2, 20266w ago Insider Cluster Bearish 5/10 Entry $361.65 to $350.40 Now $416.54 −15.18% ▲ +3.11% +3.53% vs SPY
- Sep 22, 20267w ago Institutional Cluster Mixed 4/10 Entry $368.08 to $365.27 Now $416.54 +13.17% ▼ −0.76% +0.42% vs SPY
- Sep 10, 20269w ago Insider Cluster Neutral 3/10 Entry $346.51 to $350.84 Now $416.54 +20.21% ▲ +1.25% +1.47% vs SPY
- Sep 3, 202610w ago Insider Cluster Neutral 2/10 Entry $358.26 to $353.83 Now $416.54 +16.27% ▼ −1.24% −0.03% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers